Ohtuvayre (Ensifentrine) - How effective is Ensifentrine?

Ohtuvayre (Ensifentrine) - Ensifentrine is a novel, selective dual phosphodiesterase (PDE) 3 and 4 inhibitor with bronchodilatory and anti-inflammatory effects. To evaluate the efficacy of Ohtuvayre in patients with chronic obstructive pulmonary disease (COPD), two multicenter, randomized, double-blind, parallel-group Phase III clinical trials (ENHANCE-1 and ENHANCE-2) were conducted. The primary purpose of these studies was to compare the effectiveness of exefantine versus placebo in improving lung function, symptoms, quality of life, and incidence of exacerbations in patients with COPD.

In both trials,69% and 55% of patients, respectively, received concomitant treatment with a long-acting muscarinic antagonist or a long-acting beta2-agonist. Before treatment, the patients' post-bronchodilator FEV1 percent predicted values u200bu200bwere 52% and 51%, indicating their compromised lung function.

The study results showed that compared with placebo,Ohtuvayre significantly improved the average FEV1 area under the curve within 0-12 hours. The improvement was 87 ml (95% CI: 55-119) for ENHANCE-1 and 94 ml (95% CI: 65-124) for ENHANCE-2, both of which were statistically significant (P<0.001).

Ohtuvayre was effective in improving respiratory symptoms and quality of life (as assessed by the St. George's Respiratory Questionnaire) in ENHANCE-1 at the 24-week assessment, whereas the same effect was not seen in ENHANCE-2. In addition, Ohtuvayre treatment significantly reduced the incidence of moderate or severe exacerbation, with a rate of 0.64 (95% CI: 0.40-1.00; P=0.050) for ENHANCE-1 and a rate of 0.57 (95% CI: 0.38-0.87; P=0.050) for ENHANCE-2. P=0.009), and the time to first exacerbation was also delayed, with the hazard ratio of ENHANCE-1 being 0.62 (95%CI: 0.39-0.97; P=0.038) and the hazard ratio of ENHANCE-2 being 0.58 (95%CI: 0.38-0.87; P=0.009).

Overall,Ohtuvayre demonstrated significant improvements in lung function in both clinical trials and supports its use in a broad range of COPD populations. In addition, exefantine can also reduce the risk of disease exacerbation, and its incidence of adverse events is similar to that of placebo, showing a good safety profile. These results provide strong evidence for Ohtuvayre as part of maintenance therapy for patients with COPD.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/37364283/